Company profile
Faeth Therapeutics, Inc.
NASDAQ:FTHBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SAPANISERTIB | phase2 | — | 9 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05275673 | phase2 | terminated | 2022-07-21 | 2023-01-24 | Faeth Therapeutics | A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer |
| NCT05300048 | phase1 | terminated | 2022-04-22 | 2025-04-30 | Faeth Therapeutics | Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations |
| NCT06463028 | phase2 | recruiting | 2024-12-12 | 2028-09-01 | Faeth Therapeutics | Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer |
| NCT07558733 | phase1_2 | recruiting | 2026-04-22 | 2029-05-01 | Faeth Therapeutics | Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer |
FDA applications (0)
No records yet.